Research programme: selective alpha-1A adrenoceptor antagonists - LundbeckAlternative Names: Alpha 1A adrenoceptor antagonists research programme - Lundbeck
Latest Information Update: 31 Mar 2015
At a glance
- Originator Lundbeck Research USA
- Developer Johnson & Johnson Pharmaceutical Research & Development LLC; Lundbeck Research USA; Sun Pharmaceutical Industries
- Mechanism of Action Alpha 1a adrenergic-receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Benign prostatic hyperplasia